fashion -WSS

fashion

author：comprehensive 2025-10-04 04:01:29 - browse：4945

Three boxes of Breyanzi on a dark blue background — biotech coverage from STAT — The FDA is looking into adverse events involving a number of CAR-T therapies, including Breyanzi. Illustration: STAT; Source: Business Wire

The Food and Drug Administration said Tuesday that it is investigating whether CAR-T therapy, which uses genetically modified white blood cells to attack tumors, can in rare cases cause lymphoma, a blood cancer.

“Although the overall benefits of these products continue to outweigh their potential risks for their approved uses, FDA is investigating the identified risk of T cell malignancy with serious outcomes, including hospitalization and death, and is evaluating the need for regulatory action,” the agency said in a statement.

The agency noted that it is investigating reports of T cell lymphoma, including cancer cells carrying the engineered T cells, in patients who received CAR-T therapy. Experts in the field, which has produced multiple approved products to treat blood cancer, expressed surprise and puzzlement at the announcement, saying that they had not previously seen data about the risk.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Psychedelics group wrestles with new pharma identity
Next article： Microsoft launches AI tool for clinical documentation through Epic

hotspot

WSS

Readout Newsletter: Parkinson's study, Gilead, CG Oncology

Flu vaccine reformulation won't be easy, manufacturers warn

Mass General, Mayo Clinic look to monetize custom

Merck CEO won’t testify in Senate, citing no expertise in drug prices

A pediatrician calls for Congress to pass the child tax credit deal

What causes osteoarthritis? Researchers study link to brain protein

focus

fashion

explore

As demand for Covid shots wanes, Moderna seeks its next success

Printout prescription drug information shouldn’t go digital

In age of alternative facts, a scholarly course on calling out crap

Medicare Advantage insurers face 0.2% cut to 2025 payments

United colonoscopy coverage change 'may cost lives,' doctors say

Head of FDA's diagnostics center, who led through Covid, retires

Apple is now the first public company to be valued at $3 trillion

Readout Newsletter: Parkinson's study, Gilead, CG Oncology

Bright Health sells Medicare Advantage business to Molina

White House pharmacy plagued with problems, investigation finds

knowledge

High breast density mammograms need follow

Dana Farber says 6 studies to be retracted and 31 corrected

CVS is on a mission to consolidate health care. Will it work?

Update the Apgar Score to remove skin color

Health Care Service Corp to buy Cigna Medicare Advantage plans

Venture capital firm's plans to take over Akron hospital face hurdles

explore

knowledge

hotspot

focus